

DAILY COVER

# Forbes

Market Beater  
**JAMES  
CALLINAN**

SEPTEMBER 7, 2024

# GOLDEN RULES

HOW THE OSTERWEIS OPPORTUNITY FUND TROUNCES THE INDEXES BY BUYING-AND SELLING-SMALL CAP GROWTH STOCKS WITHIN STRICT LIMITS.

PHOTO BY CODY PICKENS FOR FORBES

# This Veteran Stock Picker Beats The Market Following These Strict Rules

James Callinan's Osterweis Opportunity Fund has trounced its Russell 2000 benchmark by applying specific P/E limits for buying—and holding—small cap growth stocks.

HANK TUCKER, FORBES STAFF

---

September 7, 2024 • Premium Daily Cover

---

For most small-cap investors, 2024 has been yet another year to grumble about their chosen playground being ignored, even while trillion-dollar market-cap companies like Apple, Alphabet, Microsoft and Nvidia get ever more expensive. The Russell 2000 Index is still 14% below its November 2021 peak, while the S&P 500 has gained 15% in the same period.

The doldrums have pushed many small-cap portfolio managers to go hunting for deep value bargains. Not James Callinan—his \$365 million Osterweis Opportunity Fund is winning with the formula he's honed over nearly four decades: buy stocks with revenues and margins increasing faster than their peers, but do it with discipline.

"The small-cap indexes are filled with lousy companies," says Callinan, age 64. "Forty-five percent of the companies in the Russell 2000 don't make money. Another 20% of the index are non-growers. You probably only have around 20% of the Russell that's even investable for the growth investor."

Based in San Francisco, Callinan and his team make a living picking the right ones, and over the last 10 years, they've outperformed not only their peers but the S&P 500 as well. Osterweis posted a 13.2% 10-year annualized return through June, beating the S&P 500's 10.8% annual



CODY PICKENS FOR FORBES

**Jim Callinan (center) and co-portfolio managers Bryan Wong and Matt Unger sift through the froth in their backyard in Silicon Valley to find stocks that still have room to grow.**

---

return during that span and trouncing the 7.4% figure for its benchmark Russell 2000 Growth Index. So far this year, the fund's 18.7% return after costs—currently 1.12% of assets—is among the best in its category, with the Russell 2000 Growth's 4.4% gain lagging nine percentage points behind the S&P 500.

One of the keys to its success has been embedding strict valuation guardrails into its process despite its growth DNA. Before

Callinan invests in any stock, he expects at least 100% upside over a five-year time horizon. But he has another hard and fast (and more unusual) rule—it can't exceed an industry-specific price-to-earnings ratio to get to that doubling point.

For example, Callinan praises software as "the greatest industry in existence." Yet he won't buy a software stock that would have to rise to more than 30 times his team's five-year earnings estimate in or



der to double. That cap is around 28 times for medical devices, while semiconductor capital equipment firms get a limit of 22 times earnings, and consumer stocks are confined to a multiple in the high teens.

If that sounds a bit complicated, the rule is actually pretty simple when you see it applied. If Callinan's team estimates a software company will earn \$5 per share in five years, he won't pay more than \$75 per share for that stock today, because its share price wouldn't be able to double during that span without exceeding the 30x P/E cap.

Moreover, the rule isn't a one and done exercise. It's used on current holdings and often has helped the fund sell in time to stay out of trouble. In 2020, its best year, the fund gained 83%, fueled by the strength of stay-at-home stocks like Teladoc Health and digital health firm Livongo, which Teladoc acquired late that year. Spotting trends toward surging online traffic and ecommerce early, Osterweis started buying Teladoc and increased its stake in Livongo in the first quarter of 2020. But after both tripled in value in the first seven months of the year, the fund could no longer justify their valuations. By the end of the third quarter, Osterweis had unloaded its whole stake in both, missing out on a 30% move higher for Teladoc into early 2021—and a 97% crash since then which has haunted holders like Cathie Wood's Ark Invest.

"Once telemedicine became ubiquitous, it commoditized and everyone got into it. Covid was short-term good and long-term bad, so their competitive advantage went away," says co-portfolio manager Matt Unger. "This was kind of an easy sell, especially considering how well it did."

It's a lesson Callinan learned through several market cycles before he started the current iteration of the fund. A Harvard alum who starred at running back for its football team and is enshrined in the

school's sports hall of fame, he received an offer to try out for the New York Giants in the spring of his senior year, but stuck with his job offer in consulting and auditing at Arthur Andersen instead. Three years there and two years back at Harvard Business School led him to Putnam Investments in Boston in 1987, where he was inspired by a seminal paper by Morgan Stanley's director of research Dennis Sherva to zero in on emerging growth stocks.

In the mid-1990s, Callinan moved to San Francisco to work for Robertson Stephens Investments—just in time to live through both the inflation of the dotcom bubble and its epic bursting in March 2000. That led him to self-impose his valuation rules to mitigate risk. With few venture-backed growth companies going public in the 2000s, he created a fund with a concentrated portfolio in 2006, which is effectively the fund he still manages today after spinning out from RS Investments to go independent in 2012 and partnering in 2016 with Osterweis, a firm that offers three other mutual funds and now has \$7.4 billion in assets. Unger, 38, left RS Investments to join Callinan's team and Bryan Wong, 41, moved over from a separate Osterweis fund. Callinan named them both portfolio managers in 2021.

In the first half of this year, the Russell 2000 was propped up by a mere two stocks—data servers firm Super Micro (boosted by demand from artificial intelligence customers) and bitcoin and enterprise software play Microstrategy. Both grew so large that they graduated out of the index in June, though Super Micro has lost half its value since the start of July to trim its 2024 gains to 36%. Osterweis, despite its outperformance, owned neither. Overall, most of its portfolio is in health care, tech and consumer stocks that meet its limits.

"AI has the most long-term potential of almost any technology we've seen. I

agree with that premise, but I also think we're undergoing a little bit of a hype cycle," says Wong. "There's not a lot of AI revenue right now."

Osterweis does have some AI exposure, including a stake in semiconductor servicing firm Onto Innovation, which is up 16% this year, though much of its outperformance is coming from its picks in other sectors. Two medical device companies in its portfolio, Shockwave and Axonics, were acquired by Johnson & Johnson and Boston Scientific this year at handsome premiums. Osterweis' suite of healthcare stocks still includes Procept Biorobotics, which developed a minimally invasive way to treat enlarged prostates. Osterweis invested in the first quarter, and the stock has gained 55% since, buoyed by 74% sales growth in the last 12 months.

Fast casual salad chain Sweetgreen is another stock the fund bought in the first quarter, reaping most of the rewards of its share price tripling this year. After an expensive IPO in 2021, Sweetgreen's stock fell 80% through the end of 2023 despite its sales continuing to grow, opening an opportunity to invest at a reasonable valuation. Wong compares its 225 locations to Chipotle's 3,500 in citing its long runway for double-digit unit growth per year, and it's beginning to roll out robotic kitchens that make salads more efficiently.

The result of the volatile moves these stocks make is high churn as Osterweis takes profits or reevaluates whether to set future earnings expectations higher when stocks hit their initial price targets. The fund turns over more than 100% a year, which Callinan sees as "a feature, not a bug," if profits are realized fast enough to invest them into the next great opportunity.

"This is a category where you can make exponential-type returns on startup companies that are mysterious to a lot of investors," says Callinan. "As companies come out of that mysteriousness into the light, it can really yield multi-bag returns."



# OSTERWEIS OPPORTUNITY FUND

★★★★  
Forbes

With respect to this reprint, please note the following: The attached article has been reprinted with the permission of Forbes. The original article was first published on September 7, 2024.

*The Fund's average annual total return for the one year, three year, five year, ten year, and since-inception periods ending 6/30/2024 were as follows:*

	1 Yr	3 Yr	5 Yr	10 Yr	Since Inception (10/1/2012)
Osterweis Opportunity Fund	19.04%	-2.70%	12.22%	13.21%	14.59%
Russell 2000 Growth Index	9.14%	-4.86%	6.17%	7.39%	9.79%
S&P 500 Index	27.14	9.38	15.92	12.98	N/A

Gross/Net expense ratio as of 3/31/2024: 1.20% / 1.12%. The Adviser has contractually agreed to waive certain fees through June 30, 2025. The net expense ratio is applicable to investors.

*Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance of the Fund may be lower or higher than the performance quoted above. Performance data current to the most recent month end may be obtained by calling toll-free (866) 236-0050.*

Performance prior to December 1, 2016 is that of another investment vehicle (the "Predecessor Fund") before the commencement of the Fund's operations. The Predecessor Fund was converted into the Fund on November 30, 2016. The Predecessor Fund's performance shown includes the deduction of the Predecessor Fund's actual operating expenses. In addition, the Predecessor Fund's performance shown has been recalculated using the management fee that applies to the Fund, which has the effect of reducing the Predecessor Fund's performance. The Predecessor Fund was not a registered mutual fund and so was not subject to the same operating expenses or investment and tax restrictions as the Fund. If it had been, the Predecessor Fund's performance may have been lower.

Opinions expressed in the article are those of the author and portfolio manager. These opinions are subject to change at any time, are not guaranteed and should not be considered investment advice.

The Fund was rated 4 Stars against 550 funds Overall, 3 Stars against 550 funds over 3 Years, 5 Stars against 519 funds over 5 Years in the Small Growth category based on risk-adjusted returns as of 6/30/2024.

*The Osterweis Funds are available by prospectus only. The Funds' investment objectives, risks, charges and expenses must be considered carefully before investing. The summary and statutory prospectuses contain this and other important information about the Funds. You may obtain a summary or statutory prospectus by calling toll free at (866) 236-0050, or visiting [www.osterweis.com/statpro](http://www.osterweis.com/statpro). Please read the prospectus carefully before investing to ensure the Fund is appropriate for your goals and risk tolerance.*

**Mutual fund investing involves risk. Principal loss is possible. The Osterweis Opportunity Fund may invest in unseasoned companies, which involve additional risks such as abrupt or erratic price movements. The Fund may invest in small and mid-sized companies, which may involve greater volatility than large-sized companies. The Fund may invest in IPOs and unseasoned companies that are in the early stages of their development and may pose more risk compared to more established companies. The Fund may invest in ETFs, which involve risks that do not apply to conventional funds. Higher turnover rates may result in increased transaction costs, which could impact performance. From time to time, the Fund may have concentrated positions in one or more sectors subjecting the Fund to sector emphasis risk. The Fund may invest in foreign and emerging market securities, which involve greater volatility and political, economic and currency risks and differences in accounting methods. These risks may increase for emerging markets.**

The Russell 2000 Growth Index (Russell 2000G) is a market-capitalization-weighted index representing the small cap growth segment of U.S. equities. This index does not incur expenses, is not available for investment and includes the reinvestment of dividends.

While the fund is no-load, management fees and other expenses still apply. Please refer to the prospectus for more information.

The Morningstar Rating™ for funds, or “star rating,” is calculated for mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product’s monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period has the greatest impact because it is included in all three rating periods. The Osterweis Opportunity Fund does not have a 10-year Morningstar rating at this time.

© 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Price-to-Earnings (P/E) Ratio is the ratio of a company's stock price to its twelve months’ earnings per share.

A basis point is a unit that is equal to 1/100th of 1%.

As of 6/30/2024, the Osterweis Opportunity Fund did not own Teladoc, Super Micro, bitcoin, Microstrategy, Apple, Alphabet, Microsoft, Nvidia, or Chipotle.

The fund’s top 10 holdings as of 6/30/2024 are:

<b> Holding </b>	<b> % of Total Portfolio </b>
FirstService Corp	3.7
Skechers USA Inc-Class A	3.6
Guidewire Software Inc	3.4
FTAI Aviation Ltd	3.2
Bio-Techne Corp	3.1
elf Beauty Inc	3.1
Duolingo Inc-Class A	3.0
Ensign Group Inc	3.0
On Holding AG-Class A	3.0
MACOM Technology Solutions Holdings Inc	3.0

Fund holdings and sector allocations are subject to change and are not recommendations to buy or sell any security. *Current and future holdings are subject to risk.* Further information about the Fund’s portfolio allocation as of the last day of the most recent calendar quarter is available by visiting [https://www.osterweis.com/files/OSTGX\\_Holdings.pdf](https://www.osterweis.com/files/OSTGX_Holdings.pdf).

**Earnings growth is not representative of the Fund’s future performance.**

It is not possible to directly invest in an index.

Osterweis Capital Management is the adviser to the Osterweis Funds, which are distributed by Quasar Distributors, LLC.  
[OCMI-604310-2024-09-10]